The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of human diseases with high unmet medical need.
The Lead Discovery Center receives one million euros from the Max Planck Foundation for the development of new drug candidates.
The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need.
GlobalData’s “Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly” is now available at ReportsnReports.com.
Fostering Drug Discovery with the Significant Increase in the Number of Biobanks During 1970-2010
Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline
Page 1 of 1